戻る Agenda
Navigating Multiple Stakeholder Perspectives on Clinical HTA Methodological Standards for EU Joint Assessments beyond 2020
Session Chair(s)
Manpreet Sidhu, PHD, MBA
Executive Principal, Head of Global HTA, Health Economics, Reimbursement and Out
ICON Clinical Research, United States
Navigating the most appropriate methods for EU JCAs will be a balancing act between regulatory, national HTA and EUnetHTA standards. This forum aims to explore requirement differences from the perspectives of three relevant stakeholders
Speaker(s)
Pragmatically addressing requirements from the submitted evidence packages, and challenges in mitigating uncertainty over long-term clinical benefits: The HTA Perspective
Niklas Hedberg, MPHARM
Dental and Pharmaceutical Benefits Agency, TLV, Sweden
HTACG Co-Chair & Chief Pharmacist
Leveraging data with state-of-the-art assessment methods, and pragmatically addressing requirements across multiple countries: The Industry Perspective
Adam Parnaby
Bristol Myers Squibb, Belgium
Senior Director, Market Access Policy
EU cooperation on HTA post 2020: stronger synergies for stronger evidence
Flora Giorgio, MPHARM
European Commission, Belgium
Head of Unit Medical Devices, DG SANTE – Medical Products and Innovation